EA
GEVA

Emerald Advisers’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Emerald Advisers’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-78,545
Closed -$5.08M – 388
2013
Q4 		$5.08M Sell
78,545
-83,952
-52% -$4.98M 0.28% 122
2013
Q3 		$10.3M Buy
162,497
+14,265
+10% +$702K 0.58% 60
2013
Q2 		$6.22M Buy
+148,232
New +$6.76M 0.38% 92

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Emerald Advisers's GEVA Position: Q1 2014 in Review

Emerald Advisers sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q1 2014, closing a stake of 78,545 shares — an estimated $5.08M sold.

Emerald Advisers first reported a position in GEVA in Q2 2013 and held it in 3 quarters. The position peaked at $10.3M in Q3 2013. 115 funds tracked by Wall St. Rank hold GEVA as of Q1 2014.

  • Emerald Advisers reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q1 2014 after selling out during the quarter.
  • Emerald Advisers sold 78,545 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q1 2014, an estimated $5.08M.
  • Emerald Advisers first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 3 quarters.
  • Emerald Advisers's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $10.3M in Q3 2013.
  • 115 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q1 2014.

Based on Emerald Advisers's 13F filing for Q1 2014, filed 30 Apr 2014.